Vical Inc Antifungal VL-2397 Program Update Call
Conference Call Vical Inc
Vical Inc Conference call will be held on Oct 3, 2017. During the earnings conference call's session Vical Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Vical Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
We research and develop biopharmaceutical products, including those based on our patented DNA delivery technologies, for the prevention and treatment of serious or life-threatening diseases. We currently have four active, independent or partnered, development programs in the area of infectious disease comprised of: · An ongoing Phase 3 clinical trial of ASP0113 for prevention of cytomegalovirus, or CMV, reactivation in hematopoietic stem cell transplant recipients and an ongoing Phase 2 clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients, both in collaboration with Astellas Pharma Inc., or Astellas. Astellas expects enrollment in the Phase 3 clinical trial to be completed during the third quarter of 2016.Read more Conference Call